Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SIOX: Liquidating Distribution. Shareholders will receive $0.435 per share held. Company Dissolved. Transfer Books Closed
FINRA deleted symbol:
https://otce.finra.org/otce/dailyList?viewType=Deletions
SIOX delisted from the Nasdaq to the OTC:
https://otce.finra.org/otce/dailyList?viewType=Additions
News coming, 67 cents in net cash and net equity trading for Just 31 with special distribution or and reverse merger announcment closer day After day, read pr, deal Will be done before end of 2022
PPS at 30 cents less than half Net cash position worth 67 cents
Add NASDAQ listing, a preclinical compound and nols
Special dividend and/or Reverse merger Will let this touch a buck imo
Glty and do your dd
https://www.google.com/amp/s/www.marketscreener.com/amp/quote/stock/SIO-GENE-THERAPIES-INC-58136287/news/Sio-Gene-Therapies-Announces-Fiscal-Second-Quarter-2022-Financial-Results-42269179/
Must ready, One of the most undervalued stock ever
Huge Press release, CEO confirmed final decision above liquidation or Reverse merger in december, Hope for cash dividend worth 50 cents and Reverse merger, Easy multibagger imo
on November 13th Will be reported financial results for third quarter
Fair value around 74 cents with 74 mln shares
Float between 20 and 30 mln USD or 6/9 mln USD
This week It should hit 50 cents
Glad you got responses. Zero here. 54 million cash and tangibles, at minimum should warrant a tripple from current valuations. I'd rather see a full package buyout than partitioning. The P2 results might be the final accelerant if favorable. Should be. Were due any day now. First quarter disclosure.
CEO wrote to me several times, I exposed to him a lot of strategies for Better return for commons, He replied no one ruled out, including sale of assets, cash distribution, special dividend, buyback, reverse merger.
Every option imo Means a sure double versus current market prices
Thanks for the updates and analysis's. Now that I'm on the other forum, I can see the difference in communications and disclosures. That's been absent here.
Fwiw I still h haven't had a response from the emails and calls made to I.R.
Siox received a lot of interest and proposals, CEO said that, deals can not be executed due to lack of approvals and financings or because did not meet requirements set by Siox Bod and invest bank
Reverse merger special distribution liquidation these are the alternatives, CEO said every One Is possible
liquidation could bring more than 55 cents
Reverse merger 1 dollar
Special distribution or buyback too could fix stock PPS around Fair value or 70 cents+
Market depression let us buy this gem for peanuts and we Need to appreciate this bargain
Read them and got on stock twits. The way I see this at this point, either they've gotten interests and can close a deal or they can't. They've had since April to affect such. LOGC clearly demonstrates sector consolidation and interests. Management needs to articulate and or act. Hopefully we'll see follow through on Monday. If not, I don't see this managerial team capable of anything other than selling shares, r s, and business as usual. The P2 trial results are also over due. So maybe they'll announce this week.
Otherwise, there's no need for further speculations or discourse here imo. Speculating needs to give place to execution. Plain and simple.
Gltu
I think the best value would be a buyout around 3-4 or possibly more, depending on P2 trial results. I expected those weeks ago, so maybe Monday?
Can you provide the link to the other forum or cut paste the statements?
Increased volumes Say It all, next week SIOX 50 cents as news coming, 6 months After strategic decision made public to create value for commons
Main shareholders own 50% os
ROIVANT 25%
Easy triple imo
If liquidated could net nearly 60 cents, if merges a buck
Too much cash no debt
Read Stocktwuits, CEO replied several times and said reverse merger not the only option, that Means special distribution or liquidation too available options
Speculation about both special dividend and reverse merger
Latest take. After several emails and calls, I've gotten zero response on either. Since April's announcement on exploring options, latent P2 trial results expected first quarter, and continual depreciating market cap despite 54 million in cash and tangibles, we're either near a major reversal or the end of the end. With the Gene therapy sector gaining interests and consolidation, LOGC of latest in consolidation, we will either a see a conclusion or capitulation.
Last post here..
Looking at at minimum 8+ bag return here from current market cap on LOGC buyout alone. We're further along and have P2 trial results nearing, patent portfolio, and substantial NOLS. Merger Monday? They've been exploring options on a buyout for a longtime now. Gene sector is red hot and consolidating. Current market cap given their cash and tangibles should be at over 54 million .80 ballpark. I put SIOX in a top 3 for a big bounty return. Trading at a near 20 million mc at present.
Glta
Gene therapy sector is red hot and continues to be as a Proven immunotherapy protocol. Extremely undervalued here especially with 50+ million in cash and tangibles. We should be getting the phase II results soon. This has paper upside written all over it. It would be nice to have a shareholder update on interested parties and corporate directions on mergers.
We have LOGC bought out at 2.07 from a base of .32 and subsequent mc of sub 70 million. They had 33 million in cash tangibles and nowhere near the developments here or patents etc. There's a suit on LOGC for selling undervalued. That'll be interesting to see what develops there.
On a comparable comparison, minimum based on doubling tangibles cash, were at 110 million. $1.50 buyout. But as I wrote, given the patents, trials, nols, should be 3-6??
Tangible cash is over 50 million. Looking at .75 from sub .30s. Nice 150% return upside coming. When not if.....
Stock looks poised for an upward move. It would need to tripple to be valued at current cash and tangibles. Factor in the patents, nols, phase II test results, in play to be acquired, it's probably one of the best reward to risks plays in the small cap bio sector. I put a 3-6 buyout depending on the data released on results. I might be low on the buyout to??
Over 50 million in cash and tangibles, patent portfolio, NOLS, awaiting trial results, shopping for an acquirer, stock should be at or above a dollar at the minimum. Reward far outweighs risks here.
Some interesting buys after earnings. The logical possibility here is a buyout. Factor in current trials, NOLS, patent portfolio, cash on hand and assets, 2-4 is possible. Bring on the white night.
There's always a chance of being acquired?? Otherwise drip drip..
Thanks Urge2surge , chart tells me nothin else, and no substantial news to expect. May be SP will go up 2-4 cents or so, but nothin to hold this dog any longer.
Do you expect any positive outlook in due time here ?
ThanksHD
Stock looks ready. Should be 3 times current price for starts. Buyout range $3 IMO.
Over 60 million in cash and equivalents, zero debt, in play for take over, factoring in patent portfolio, Nols, chart technicals, we're looking for a tripple at minimum from here.. Buy out IMO is north of $2.
SIOX buy 0.430600
nice exhaustion gap and now reversal buy
find the massive macd bullish divergence on the daily and weekly charts
it just broke above the downtrend line as a buy trigger for the setup
up we go
https://siogtx.com/
https://finance.yahoo.com/quote/SIOX/profile?p=SIOX
https://www.barchart.com/stocks/quotes/SIOX
https://finviz.com/quote.ashx?t=SIOX
https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=SIOX
https://stockcharts.com/c-sc/sc?chart=SIOX,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b
https://www.barchart.com/etfs-funds/quotes/SIOX/technical-chart?plot=CANDLE&volume=toSIOX&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=TREND&sym=SIOX&grid=1&height=500&studyheight=100&timeframe=2%20Months
normal chart
log chart
normal chart
log chart
Another small cap bio that won't hunt. Below cash value too. Got out and the last bio I'll play. They're all dogs with zero return on investment monies.
News and PPS down again and again. Stioll watch.
SIOX
Trading at cash value. Price target 1 dollar. Operations in full buyout now IMO.
Over 30% below cash value, with a potential Parkinson's treatment. Amazing times..
Currently below tangible book value here. With the Parkinson's prom is potential promise of a viable treatment, can the market cap be any more insulting?
Within 6 months SIOX could easily be 1000% (10X) higher than its current price.
Good luck and GOD bless,
TODAY’s update from Sio Gene Therapies
https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-corporate-updates-and-fiscal-second
Good luck and GOD bless,
Regard SIOX and AXO-lento- PD
See slides 32 thru 37 inclusive
https://www.oxb.com/system/files/corporate-presentations/OXB%20Presentation%2027%20Oct%2021%20w%20appendix.pdf
Good luck and GOD bless,
GREAT news this morning 3 batches at date I say 200 liter batch size.
That is EXCELLENT NEWS. That should be enough material to treat 10s of thousands if not hundreds of thousands of men and women with Parkinson’s’ disease.
Ready for commercialization.
“Today’s announcement is the culmination of several months of effort by the Sio and Oxford BioMedica teams focused on the development of a reliable, suspension-based manufacturing process to enable scale-up of production and advancement of the AXO-Lenti-PD program,” said Pavan Cheruvu, M.D., Chief Executive Officer of Sio Gene Therapies. “With the successful manufacture of three batches, all of which achieved the target titer and have completed fill and finish, we now have a process that has generated sufficient clinical trial material for future clinical development. We believe these data, coupled with scientific advice from the MHRA, help clarify the path forward and collectively represent an inflection point for the AXO-Lenti-PD program.”
https://finance.yahoo.com/news/sio-gene-therapies-announces-successful-120000897.html
Good luck and GOD bless,